Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Bewertung der Wirksamkeit und Sicherheit von Belantamab Mafodotin, Bortezomib und Dexamethason im Vergleich zu Daratumumab, Bortezomib und Dexamethason bei Teilnehmern mit rezidiviertem/refraktärem multiplem Myelom (DREAMM 7)

29. Oktober 2026 aktualisiert von: GlaxoSmithKline

DREAMM 7: Eine multizentrische, offene, randomisierte Phase-III-Studie zur Bewertung der Wirksamkeit und Sicherheit der Kombination von Belantamab Mafodotin, Bortezomib und Dexamethason (B-Vd) im Vergleich zur Kombination von Daratumumab, Bortezomib und Dexamethason (D-Vd ) bei Teilnehmern mit rezidiviertem/refraktärem Multiplem Myelom

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

494

Phase

  • Phase 3

Erweiterter Zugriff

Genehmigt zum Verkauf an die Öffentlichkeit. Siehe erweiterter Zugriffsdatensatz.

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • New South Wales
      • Camperdown, New South Wales, Australien, 2050
        • GSK Investigational Site
      • Liverpool, New South Wales, Australien, 2170
        • GSK Investigational Site
      • Newcastle, New South Wales, Australien, 2298
        • GSK Investigational Site
      • St Leonards, New South Wales, Australien, 2065
        • GSK Investigational Site
      • Wollongong, New South Wales, Australien, 2500
        • GSK Investigational Site
    • Queensland
      • Benowa, Queensland, Australien, 4217
        • GSK Investigational Site
      • Herston, Queensland, Australien, 4029
        • GSK Investigational Site
    • South Australia
      • Ashford, South Australia, Australien, 5037
        • GSK Investigational Site
    • Victoria
      • Box Hill, Victoria, Australien, 3128
        • GSK Investigational Site
      • Heidelberg, Victoria, Australien, 3084
        • GSK Investigational Site
      • Melbourne, Victoria, Australien, 3004
        • GSK Investigational Site
    • Western Australia
      • Murdoch, Western Australia, Australien, 6150
        • GSK Investigational Site
      • Nedlands, Western Australia, Australien, 6009
        • GSK Investigational Site
      • Roeselare, Belgien, 8800
        • GSK Investigational Site
    • Brussels Capital
      • Jette, Brussels Capital, Belgien, 1090
        • GSK Investigational Site
      • Woluwé-Saint-Lambert, Brussels Capital, Belgien, 1200
        • GSK Investigational Site
    • Oost-Vlaanderen
      • Ghent, Oost-Vlaanderen, Belgien, 9000
        • GSK Investigational Site
      • Joinville, Brasilien, 89201-260
        • GSK Investigational Site
      • Natal, Brasilien, 59075-740
        • GSK Investigational Site
      • Rio de Janeiro, Brasilien, 22775001
        • GSK Investigational Site
      • São Paulo, Brasilien, 04537-080
        • GSK Investigational Site
      • São Paulo, Brasilien, 05403-000
        • GSK Investigational Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90035-903
        • GSK Investigational Site
    • Santa Catarina
      • Florianópolis, Santa Catarina, Brasilien, 88020-210
        • GSK Investigational Site
      • Beijing, China, 100191
        • GSK Investigational Site
      • Beijing, China, 100020
        • GSK Investigational Site
      • Changchun, China, 130012
        • GSK Investigational Site
      • Guangzhou, China, 510060
        • GSK Investigational Site
      • Guangzhou, China, 510515
        • GSK Investigational Site
      • Hangzhou, China, 310003
        • GSK Investigational Site
      • Jinan, China, 250012
        • GSK Investigational Site
      • Nanjing, China, 210008
        • GSK Investigational Site
      • Shenyang, China, 110001
        • GSK Investigational Site
      • Suzhou, China, 215006
        • GSK Investigational Site
      • Tianjin, China, 300020
        • GSK Investigational Site
      • Zhengzhou, China, 450052
        • GSK Investigational Site
      • Cologne, Deutschland, 50937
        • GSK Investigational Site
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Deutschland, 89081
        • GSK Investigational Site
    • Bavaria
      • München, Bavaria, Deutschland, 81377
        • GSK Investigational Site
      • Würzburg, Bavaria, Deutschland, 97080
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Düsseldorf, North Rhine-Westphalia, Deutschland, 40225
        • GSK Investigational Site
    • Thuringia
      • Jena, Thuringia, Deutschland, 07747
        • GSK Investigational Site
      • Amiens, Frankreich, 80054
        • GSK Investigational Site
      • Caen, Frankreich, 14033
        • GSK Investigational Site
      • Nice, Frankreich, 06200
        • GSK Investigational Site
      • Paris, Frankreich, 75651
        • GSK Investigational Site
      • Rennes, Frankreich, 35033
        • GSK Investigational Site
      • Athens, Griechenland, 11528
        • GSK Investigational Site
      • Thessaloniki, Griechenland, 54007
        • GSK Investigational Site
    • East Macedonia and Thrace
      • Alexandroupoli, East Macedonia and Thrace, Griechenland, 681 00
        • GSK Investigational Site
      • Jerusalem, Israel, 91120
        • GSK Investigational Site
      • Kfar Saba, Israel, 44281
        • GSK Investigational Site
      • Ramat Gan, Israel, 52621
        • GSK Investigational Site
      • Tel Aviv, Israel, 64239
        • GSK Investigational Site
      • Bergamo, Italien, 24127
        • GSK Investigational Site
      • Bologna, Italien, 40138
        • GSK Investigational Site
      • Brescia, Italien, 25123
        • GSK Investigational Site
      • Catania, Italien, 95123
        • GSK Investigational Site
      • Meldola FC, Italien, 47014
        • GSK Investigational Site
      • Milan, Italien, 20133
        • GSK Investigational Site
      • Ravenna, Italien, 48121
        • GSK Investigational Site
      • Roma, Italien, 00168
        • GSK Investigational Site
      • Siena, Italien, 53100
        • GSK Investigational Site
      • Torino, Italien, 10126
        • GSK Investigational Site
      • Aichi, Japan, 467-8602
        • GSK Investigational Site
      • Aichi, Japan, 441-8570
        • GSK Investigational Site
      • Aomori, Japan, 030-8553
        • GSK Investigational Site
      • Ehime, Japan, 790-8524
        • GSK Investigational Site
      • Fukuoka, Japan, 806-8501
        • GSK Investigational Site
      • Fukuoka, Japan, 807-8555
        • GSK Investigational Site
      • Fukuoka, Japan, 810-8563
        • GSK Investigational Site
      • Fukuoka, Japan, 815-8555
        • GSK Investigational Site
      • Gifu, Japan, 503-8502
        • GSK Investigational Site
      • Gunma, Japan, 377-0280
        • GSK Investigational Site
      • Hyōgo, Japan, 670-8540
        • GSK Investigational Site
      • Kanagawa, Japan, 247-8533
        • GSK Investigational Site
      • Kanagawa, Japan, 221-0855
        • GSK Investigational Site
      • Kochi, Japan, 781-8555
        • GSK Investigational Site
      • Nagano, Japan, 392-8510
        • GSK Investigational Site
      • Okayama, Japan, 701-1192
        • GSK Investigational Site
      • Osaka, Japan, 545-8586
        • GSK Investigational Site
      • Osaka, Japan, 530-0012
        • GSK Investigational Site
      • Shizuoka, Japan, 411-8777
        • GSK Investigational Site
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 1Z2
        • GSK Investigational Site
    • Ontario
      • London, Ontario, Kanada, N6A 5W9
        • GSK Investigational Site
      • Toronto, Ontario, Kanada, M4N 3M5
        • GSK Investigational Site
    • Quebec
      • Montreal, Quebec, Kanada, H4J 1C5
        • GSK Investigational Site
      • Christchurch, Neuseeland, 8011
        • GSK Investigational Site
      • Dunedin, Neuseeland, 9054
        • GSK Investigational Site
      • Takapuna Auckland, Neuseeland, 1309
        • GSK Investigational Site
      • Wellington, Neuseeland, 6021
        • GSK Investigational Site
      • Groningen, Niederlande, 9713 GZ
        • GSK Investigational Site
    • South Holland
      • Dordrecht, South Holland, Niederlande, 3318 AT
        • GSK Investigational Site
      • Chorzów, Polen, 41-500
        • GSK Investigational Site
      • Krakow, Polen, 30510
        • GSK Investigational Site
      • Lodz, Polen, 93-513
        • GSK Investigational Site
      • Lublin, Polen, 20-081
        • GSK Investigational Site
      • Lublin, Polen, 20-090
        • GSK Investigational Site
      • Nowy Sącz, Polen, 33-300
        • GSK Investigational Site
      • Poznan, Polen, 60-569
        • GSK Investigational Site
      • Warsaw, Polen, 02-781
        • GSK Investigational Site
      • Moscow, Russland, 125284
        • GSK Investigational Site
      • Nizhny Novgorod, Russland, 603126
        • GSK Investigational Site
      • Novosibirsk, Russland, 630087
        • GSK Investigational Site
      • Saint Petersburg, Russland, 191024
        • GSK Investigational Site
      • Saint Petersburg, Russland, 197 089
        • GSK Investigational Site
      • Samara, Russland, 443021
        • GSK Investigational Site
      • Saratov, Russland, 410028
        • GSK Investigational Site
      • Ufa, Russland, 450083
        • GSK Investigational Site
      • Barcelona, Spanien, 08035
        • GSK Investigational Site
      • Barcelona, Spanien, 08916
        • GSK Investigational Site
      • Cáceres, Spanien, 10003
        • GSK Investigational Site
      • Gijón, Spanien, 33394
        • GSK Investigational Site
      • L'Hospitalet de Llobrega, Spanien, 08908
        • GSK Investigational Site
      • MOstoles Madrid, Spanien, 28933
        • GSK Investigational Site
      • Madrid, Spanien, 28007
        • GSK Investigational Site
      • Madrid, Spanien, 31008
        • GSK Investigational Site
      • Murcia, Spanien, 30008
        • GSK Investigational Site
      • PamplonaNavarra, Spanien, 31008
        • GSK Investigational Site
      • Pozuelo de AlarcOn Madr, Spanien, 28223
        • GSK Investigational Site
      • Salamanca, Spanien, 37007
        • GSK Investigational Site
      • Pusan, Südkorea, 49241
        • GSK Investigational Site
      • Seongnam-si Gyeonggi-do, Südkorea, 13620
        • GSK Investigational Site
      • Seoul, Südkorea, 06351
        • GSK Investigational Site
      • Seoul, Südkorea, 06591
        • GSK Investigational Site
      • Ulsan, Südkorea, 44033
        • GSK Investigational Site
      • Brno, Tschechien, 625 00
        • GSK Investigational Site
      • Hradec Králové, Tschechien, 500 05
        • GSK Investigational Site
      • Ostrava, Tschechien, 708 52
        • GSK Investigational Site
      • Prague, Tschechien, 128 08
        • GSK Investigational Site
    • Arizona
      • Yuma, Arizona, Vereinigte Staaten, 85364
        • GSK Investigational Site
    • Kansas
      • Mission, Kansas, Vereinigte Staaten, 66205-2005
        • GSK Investigational Site
    • North Carolina
      • Denver, North Carolina, Vereinigte Staaten, 80128
        • GSK Investigational Site
    • Ohio
      • Blue Ash, Ohio, Vereinigte Staaten, 45242-5665
        • GSK Investigational Site
    • Texas
      • Tyler, Texas, Vereinigte Staaten, 75702
        • GSK Investigational Site
    • Virginia
      • Roanoke, Virginia, Vereinigte Staaten, 24014
        • GSK Investigational Site
      • Bournemouth, Vereinigtes Königreich, BH7 7DW
        • GSK Investigational Site
      • Cardiff, Vereinigtes Königreich, CF14 4XW
        • GSK Investigational Site
      • Dundee, Vereinigtes Königreich, DD1 9SY
        • GSK Investigational Site
      • Leicester, Vereinigtes Königreich, LE1 5WW
        • GSK Investigational Site
      • London, Vereinigtes Königreich, W12 0NN
        • GSK Investigational Site
      • Stoke-on-Trent, Vereinigtes Königreich, ST4 6QG
        • GSK Investigational Site
      • Sutton, Vereinigtes Königreich, SM2 5PT
        • GSK Investigational Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.

  • Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

  • Must have at least 1 aspect of measurable disease, defined as one of the following;

    1. Urine M-protein excretion >=200 mg per 24-hour, or
    2. Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
    3. Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
  • All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.

  • Adequate organ function

Exclusion Criteria:

  • Intolerant to daratumumab.
  • Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
  • Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
  • Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
  • Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
  • Prior allogenic stem cell transplant.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
  • Corneal epithelial disease.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Belantamab Mafodotin und Bortezomib plus Dexamethason (Arm A)

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

Aktiver Komparator: Daratumumab und Bortezomib plus Dexamethason (Arm B)

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

Anti-cluster of differentiation 38 [CD-38] monoclonal antibody

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Progression-free Survival (PFS)
Zeitfenster: Up to approximately 41 months

PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis.

Up to approximately 41 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Anzahl der Teilnehmer mit abnormalen Augenbefunden bei der augenärztlichen Untersuchung
Zeitfenster: Bis zu 73 Monate
Bis zu 73 Monate
Complete Response Rate (CRR)
Zeitfenster: Up to 73 months

CRR is defined as percentage of participants with a confirmed complete response or better.

Up to 73 months
Overall Response Rate (ORR)
Zeitfenster: Up to 73 months

ORR is defined as percentage of participants with a confirmed partial response or better.

Up to 73 months
Clinical Benefit Rate (CBR)
Zeitfenster: Up to 73 months

CBR is defined as percentage of participants with a confirmed minimal response (MR) or better

Up to 73 months
Duration of Response (DoR)
Zeitfenster: Up to 73 months

DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first.

Up to 73 months
Time to Response (TTR)
Zeitfenster: Up to 73 months

TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better.

Up to 73 months
Time to Progression (TTP)
Zeitfenster: Up to 73 months

TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first.

Up to 73 months
Overall Survival (OS)
Zeitfenster: Up to 73 months

OS is defined as time from the date of randomization until the date of death due to any cause.

Up to 73 months
Progression-free Survival on Subsequent Line of Therapy (PFS2)
Zeitfenster: Up to 73 months

Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.

Up to 73 months
Minimal Residual Disease (MRD) Negativity Rate
Zeitfenster: Up to 73 months

Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS).

Up to 73 months
Number of Participants With Adverse Events (AEs)
Zeitfenster: Up to 73 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

Up to 73 months
Number of Participants With Clinically Significant Changes in Hematology Parameters
Zeitfenster: Up to 73 months

Blood samples will be collected for the analysis of hematology parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Clinical Chemistry
Zeitfenster: Up to 73 months

Blood samples will be collected for the analysis of clinical chemistry parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Urine Dipstick
Zeitfenster: Up to 73 months

Urine samples will be collected for the urine dipstick analysis.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
Zeitfenster: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
Zeitfenster: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
Zeitfenster: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Zeitfenster: Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.

Up to 73 months
Titers of ADAs Against Belantamab Mafodotin
Zeitfenster: Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers.

Up to 73 months
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
Zeitfenster: Up to 73 months

The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.

Up to 73 months
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
Zeitfenster: Up to 73 months

The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Up to 73 months
Change From Baseline in HRQoL as Measured by EORTC IL52
Zeitfenster: Up to 73 months

The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning.

Up to 73 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: GSK Clinical Trials, GlaxoSmithKline

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

7. Mai 2020

Primärer Abschluss (Tatsächlich)

2. Oktober 2023

Studienabschluss (Geschätzt)

8. Oktober 2029

Studienanmeldedaten

Zuerst eingereicht

27. Januar 2020

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

27. Januar 2020

Zuerst gepostet (Tatsächlich)

29. Januar 2020

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

29. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .